MXPA05000617A - Uso de un derivado de amina ciclica especifica o las sales farmaceuticamente aceptables del mismo para el tratamiento o prevencion de insuficiencia cardiaca. - Google Patents

Uso de un derivado de amina ciclica especifica o las sales farmaceuticamente aceptables del mismo para el tratamiento o prevencion de insuficiencia cardiaca.

Info

Publication number
MXPA05000617A
MXPA05000617A MXPA05000617A MXPA05000617A MXPA05000617A MX PA05000617 A MXPA05000617 A MX PA05000617A MX PA05000617 A MXPA05000617 A MX PA05000617A MX PA05000617 A MXPA05000617 A MX PA05000617A MX PA05000617 A MXPA05000617 A MX PA05000617A
Authority
MX
Mexico
Prior art keywords
heart failure
cilobradine
treatment
pharmaceutically acceptable
use according
Prior art date
Application number
MXPA05000617A
Other languages
English (en)
Spanish (es)
Inventor
Randolph Seidler
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29265956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05000617(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA05000617A publication Critical patent/MXPA05000617A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05000617A 2002-07-25 2003-07-21 Uso de un derivado de amina ciclica especifica o las sales farmaceuticamente aceptables del mismo para el tratamiento o prevencion de insuficiencia cardiaca. MXPA05000617A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016602A EP1362590B1 (en) 2002-07-25 2002-07-25 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
PCT/EP2003/007929 WO2004011006A1 (en) 2002-07-25 2003-07-21 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Publications (1)

Publication Number Publication Date
MXPA05000617A true MXPA05000617A (es) 2005-08-19

Family

ID=29265956

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000617A MXPA05000617A (es) 2002-07-25 2003-07-21 Uso de un derivado de amina ciclica especifica o las sales farmaceuticamente aceptables del mismo para el tratamiento o prevencion de insuficiencia cardiaca.

Country Status (29)

Country Link
US (1) US20130317008A1 (https=)
EP (2) EP1362590B1 (https=)
JP (3) JP2005533853A (https=)
KR (1) KR20050074432A (https=)
CN (1) CN100502874C (https=)
AR (1) AR040690A1 (https=)
AT (2) ATE257384T1 (https=)
AU (1) AU2003254554B8 (https=)
BR (1) BR0312852A (https=)
CA (1) CA2493208C (https=)
CO (1) CO5700723A2 (https=)
CY (1) CY1112173T1 (https=)
DE (1) DE60200160T2 (https=)
DK (2) DK1362590T3 (https=)
ES (2) ES2211846T3 (https=)
HR (1) HRP20050075B1 (https=)
MX (1) MXPA05000617A (https=)
MY (1) MY128529A (https=)
NZ (1) NZ538424A (https=)
PE (1) PE20040706A1 (https=)
PL (1) PL214716B1 (https=)
PT (2) PT1362590E (https=)
SA (1) SA03240350B1 (https=)
SI (2) SI1362590T1 (https=)
TR (1) TR200400127T4 (https=)
TW (1) TWI319321B (https=)
UY (1) UY27910A1 (https=)
WO (1) WO2004011006A1 (https=)
ZA (1) ZA200500084B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
JPWO2007023775A1 (ja) * 2005-08-23 2009-02-26 アステラス製薬株式会社 心房細動治療剤
EP1762179A1 (en) 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2927538B1 (fr) 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
WO2013024036A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim Vetmedica Gmbh Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline
WO2014122248A1 (en) 2013-02-11 2014-08-14 Boehringer Ingelheim Vetmedica Gmbh Kit-of-parts

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JP4240173B2 (ja) * 1998-06-03 2009-03-18 日産化学工業株式会社 インダン誘導体
DE60009287T2 (de) * 1999-06-03 2005-02-17 Yamanouchi Pharmaceutical Co., Ltd. Neuartige isoquinolin-derivate oder salze davon
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
EP1362590B1 (en) * 2002-07-25 2004-01-07 Boehringer Ingelheim Pharma GmbH & Co.KG Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure

Also Published As

Publication number Publication date
CN1671392A (zh) 2005-09-21
EP1534296A1 (en) 2005-06-01
ES2211846T3 (es) 2004-07-16
DK1534296T3 (da) 2011-08-15
CO5700723A2 (es) 2006-11-30
NZ538424A (en) 2006-10-27
WO2004011006A1 (en) 2004-02-05
AU2003254554A1 (en) 2004-02-16
JP2005533853A (ja) 2005-11-10
BR0312852A (pt) 2005-04-19
CA2493208C (en) 2011-11-01
SA03240350B1 (ar) 2007-10-29
UY27910A1 (es) 2004-02-27
CN100502874C (zh) 2009-06-24
TR200400127T4 (tr) 2004-02-23
TWI319321B (en) 2010-01-11
DE60200160T2 (de) 2004-11-04
HRP20050075B1 (hr) 2013-12-20
EP1362590A1 (en) 2003-11-19
KR20050074432A (ko) 2005-07-18
AU2003254554B8 (en) 2009-02-26
TW200412974A (en) 2004-08-01
SI1534296T1 (sl) 2011-09-30
SI1362590T1 (sl) 2004-04-30
US20130317008A1 (en) 2013-11-28
JP2009256379A (ja) 2009-11-05
PT1362590E (pt) 2004-05-31
HRP20050075A2 (en) 2005-12-31
EP1362590B1 (en) 2004-01-07
ZA200500084B (en) 2005-10-26
AR040690A1 (es) 2005-04-13
PE20040706A1 (es) 2004-12-06
ES2367109T3 (es) 2011-10-28
PL372993A1 (en) 2005-08-08
ATE510543T1 (de) 2011-06-15
DE60200160D1 (de) 2004-02-12
CA2493208A1 (en) 2004-02-05
JP2013166781A (ja) 2013-08-29
DK1362590T3 (da) 2004-03-29
CY1112173T1 (el) 2015-12-09
AU2003254554B2 (en) 2009-01-29
EP1534296B1 (en) 2011-05-25
EP1362590A8 (en) 2004-02-25
PL214716B1 (pl) 2013-09-30
MY128529A (en) 2007-02-28
ATE257384T1 (de) 2004-01-15
PT1534296E (pt) 2011-08-18

Similar Documents

Publication Publication Date Title
US20130317008A1 (en) Use of a Specific Cyclic Amine Derivative or the Pharmaceutically Acceptable Salts Thereof for the Treatment or Prevention of Heart Failure
US8524701B2 (en) Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
AU2016282985B2 (en) Combination therapy of cardiac myosin activator and sinus node if current inhibitor
US20260102472A1 (en) Semaglutide in medical therapy
US20140171415A1 (en) Funny current (if) inhibitors for use in a method of treating and preventing heart disease in canine
US20040209885A1 (en) Combination therapy for the treatment of heart failure
US20110313006A1 (en) PHARMACEUTICAL COMPOSITION OF LEVAMLODIPINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND β RECEPTOR BLOCKING AGENT, AND USE THEREOF
CA2435526A1 (en) Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CN101869562A (zh) 左旋氨氯地平复方药物制剂
CN106310267A (zh) 脑啡肽酶抑制剂、血管紧张素受体阻断剂与叶酸的组合物
Fogari et al. Effect of sustained-release diltiazem on ambulatory blood pressure and left ventricular mass in elderly patients with hypertension
JPH0827029A (ja) 5ht1 作動薬の新規医薬用途
HK1152897B (en) Combined use of valsartan and calcium channel blockers for therapeutic purposes

Legal Events

Date Code Title Description
FG Grant or registration